Disease or Syndrome
Sanofi Expands Immunology Pipeline with $600M Acquisition of Dren Bio’s Novel B-Cell Depleting Bispecific Antibody
Bispecific antibody, Myeloid cell engager, B-cell depletion, Autoimmune diseases, Immunology pipeline, Phagocytosis, CD20-directed therapy
Paratek Expands into Chronic Rhinosinusitis Market with $330M Optinose Acquisition
Paratek Pharmaceuticals, Optinose , XHANCE, Chronic rhinosinusitis, Nasal drug delivery, Pharmaceutical acquisition, Specialty pharma
ReSync Bio, Sapio Sciences adopt Nvidia BioNeMo to supercharge AI drug discovery
Drug Discovery, Aortic Valve Insufficiency, Sapio, Sapio Sciences, Bio, NVIDIA ‘s, BioNeMo, microservices
Novartis Prepares to File Intrathecal Zolgensma for Older SMA Patients by Mid-2025
Zolgensma, intrathecal delivery, spinal muscular atrophy, gene therapy, older patients
Immunovant Shifts Focus to Next-Gen Drug Despite Positive Phase 3 Results for Batoclimab in Myasthenia Gravis
Immunovant, batoclimab, myasthenia gravis, Phase 3 success, IMVT-1402, FcRn inhibitor, autoimmune disorders
Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes
Continuous Glucose Monitoring System, Technology, Health Personnel, CGM, Diabetes Mellitus, Non-Insulin-Dependent
Trump Administration Considers Cuts to CDC’s HIV Prevention Program, Raising Concerns
HIV prevention, CDC funding cuts, Trump administration, public health, HIV/AIDS advocacy
Sarepta Reports Death of DMD Patient Following Elevidys Gene Therapy Treatment
Sarepta, Elevidys, gene therapy, Duchenne muscular dystrophy, patient death, acute liver failure
Arch-backed HC Bioscience closes doors after seeing early data for tRNA asset
Vision, hydrocortisone, Bioscience
Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy
Gene editing, CRISPR, Rare liver disease, Primary hyperoxaluria type 1 (PH1), Funding